Please assess the completion status of the following clinical trial:

Trial Title: ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Primary Inclusion Criteria:~* Written, informed consent~* 18 years of age or older~* Current diagnosis of opioid dependence, based on Diagnostic and Statistical Manual of Mental Health Disorders, 4th Ed. (DSM-IV-TR) criteria~* Voluntarily seeking treatment for opioid dependence~* Completing or recently completed up to 30 days of inpatient treatment for opioid detoxification, and off all opioids (including buprenorphine and methadone) for at least 7 days~* Noncustodial, stable residence and phone, plus 1 contact with verifiable address and phone~* Significant other (eg, spouse, relative) willing to supervise compliance with the study visit schedule and procedures~* Agree to use contraception for study duration if of childbearing potential~Primary Exclusion Criteria:~* Pregnancy or lactation~* Clinically significant medical condition or observed abnormalities (eg: physical exam, electrocardiogram (ECG), lab and/or urinalysis findings)~* Positive naloxone challenge test at randomization (Day 0)~* Evidence of hepatic failure including: ascites, bilirubin \>10% above upper limit of normal (ULN) and/or esophageal variceal disease~* Past or present history of an acquired immunodeficiency syndrome (AIDS)-indicator disease in HIV-infected subjects~* Active hepatitis and/or aspartate aminotransferase (AST), alanine aminotransferase(ALT) \>3xULN~* Current major depression with suicidal ideation, psychosis, bipolar disorder, or any psychiatric disorder that would compromise ability to complete the study~* Recent history (within 6 months prior to screening) of suicidal ideation or attempt~* Dependence within prior year based on DSM-IV-TR, to any drugs other than prescription opioids or heroin, caffeine, marijuana, or nicotine~* Active alcohol dependence within prior 6 months~* Current alcohol use disorder that would, in the Investigator's opinion, preclude successful completion of the study~* Positive urine drug test for cocaine, benzodiazepines, or amphetamines at screening~* Use of oral naltrexone for 7 consecutive days within 60 days prior to screening~* Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or polylactide-co-glycolide (PLG)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VIVITROL® 380 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).